Terms: = Leukemia AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2
738 results:
1. Cytogenetic abnormalities and TP53 and RAS gene profiles of childhood acute lymphoblastic leukemia in Morocco.
Skhoun H; El Fessikh M; El Alaoui Al Abdallaoui M; Khattab M; Belkhayat A; Chebihi ZT; Hassani A; Abilkassem R; Agadr A; Dakka N; El Baghdadi J
Arch Pediatr; 2024 May; 31(4):238-244. PubMed ID: 38679547
[TBL] [Abstract] [Full Text] [Related]
2. The RAS-signaling-pathway-mutation-related prognosis in B-cell acute lymphoblastic leukemia: A report from South China children's leukemia group.
Li X; Lin S; Liao N; Mai H; Long X; Liu L; Wu B; Chen Q; Kong Q; Kong X; Liu L; Qin J; Fang J; Zhou D
Hematol Oncol; 2024 May; 42(3):e3265. PubMed ID: 38564328
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic implications of cGAS and STING gene expression in acute myeloid leukemia.
Chen Q; Hong Y; Chen W; Lin F; Zeng J; Huang Y; Zhang L; Yao J; Xu B
Exp Biol Med (Maywood); 2024; 249():10108. PubMed ID: 38510490
[TBL] [Abstract] [Full Text] [Related]
4. AML with RUNX1::RUNX1T1 Cooperating two Mutations Relapsed Quickly after Achieving CR.
XinhongYang ; Wu Y; Yang X; Wu X; Chen Y; Zhang R; Zhang Z
Clin Lab; 2024 Mar; 70(3):. PubMed ID: 38469780
[TBL] [Abstract] [Full Text] [Related]
5. Integrated analysis of transcriptome and genome variations in pediatric T cell acute lymphoblastic leukemia: data from north Indian tertiary care center.
Singh M; Sharma P; Bhatia P; Trehan A; Thakur R; Sreedharanunni S
BMC Cancer; 2024 Mar; 24(1):325. PubMed ID: 38459434
[TBL] [Abstract] [Full Text] [Related]
6. 5G2 mutant mice model loss of a commonly deleted segment of chromosome 7q22 in myeloid malignancies.
Wong JC; Weinfurtner KM; Westover T; Kim J; Lebish EJ; Del Pilar Alzamora M; Huang BJ; Walsh M; Abdelhamed S; Ma J; Klco JM; Shannon K
Leukemia; 2024 May; 38(5):1182-1186. PubMed ID: 38443608
[TBL] [Abstract] [Full Text] [Related]
7. Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
Mata DA; Lee JK; Shanmugam V; Marcus CB; Schrock AB; Williams EA; Ritterhouse LL; Hickman RA; Janovitz T; Patel NR; Kroger BR; Ross JS; Mirza KM; Oxnard GR; Vergilio JA; Elvin JA; Benhamida JK; Decker B; Xu ML
Histopathology; 2024 Jun; 84(7):1224-1237. PubMed ID: 38422618
[TBL] [Abstract] [Full Text] [Related]
8. Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia.
Bouligny IM; Murray G; Doyel M; Patel T; Boron J; Tran V; Gor J; Hang Y; Alnimer Y; Ho T; Zacholski K; Venn C; Wages NA; Grant S; Maher KR
Med Oncol; 2024 Feb; 41(3):80. PubMed ID: 38396145
[TBL] [Abstract] [Full Text] [Related]
9. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
Shimony S; Bewersdorf JP; Shallis RM; Liu Y; Schaefer EJ; Zeidan AM; Goldberg AD; Stein EM; Marcucci G; Lindsley RC; Chen EC; Ramos Perez J; Stein A; DeAngelo DJ; Neuberg DS; Stone RM; Ball B; Stahl M
Leukemia; 2024 Apr; 38(4):762-768. PubMed ID: 38378841
[TBL] [Abstract] [Full Text] [Related]
10. Histiocytic sarcoma following CAR T-cell therapy: a case report.
An K; He Y; Tang Y; Gu X; Qian J; Li B
Int J Hematol; 2024 Mar; 119(3):338-341. PubMed ID: 38294639
[TBL] [Abstract] [Full Text] [Related]
11. Demographics and additional haematologic cancers of patients with histiocytic/dendritic cell neoplasms.
Kemps PG; Kester L; Scheijde-Vermeulen MA; van Noesel CJM; Verdijk RM; Diepstra A; van Marion AMW; Dors N; van den Bos C; Bruggink AH; Hogendoorn PCW; van Halteren AGS
Histopathology; 2024 Apr; 84(5):837-846. PubMed ID: 38213281
[TBL] [Abstract] [Full Text] [Related]
12. Correlation of miR-155-5p, kras, and CREB Expression in Patients with Acute Myeloid leukemia.
Garavand J; Mohammadi MH; Jalali MT; Saki N
Clin Lab; 2024 Jan; 70(1):. PubMed ID: 38213224
[TBL] [Abstract] [Full Text] [Related]
13. Transcriptome analysis of primary adult B-cell lineage acute lymphoblastic leukemia identifies pathogenic variants and gene fusions, and predicts subtypes for in depth molecular diagnosis.
Podgorica M; Drivet E; Viken JK; Richman A; Vestbøstad J; Szodoray P; Kvam AK; Wik HS; Tjønnfjord GE; Munthe LA; Frietze S; Schjerven H
Eur J Haematol; 2024 May; 112(5):731-742. PubMed ID: 38192186
[TBL] [Abstract] [Full Text] [Related]
14. [Clinical and molecular biological characterization of patients with accelerated chronic lymphocytic leukemia].
Zhou ZY; Dai LMJ; Sha YQ; Qiu TL; Qin SC; Miao Y; Xia Y; Wu W; Tang HN; Xu W; Li JY; Zhu HY
Zhonghua Xue Ye Xue Za Zhi; 2023 Nov; 44(11):917-923. PubMed ID: 38185521
[No Abstract] [Full Text] [Related]
15. NLRP3 inflammasome activation and symptom burden in kras-mutated CMML patients is reverted by IL-1 blocking therapy.
Hurtado-Navarro L; Cuenca-Zamora EJ; Zamora L; Bellosillo B; Such E; Soler-Espejo E; Martínez-Banaclocha H; Hernández-Rivas JM; Marco-Ayala J; Martínez-Alarcón L; Linares-Latorre L; García-Ávila S; Amat-Martínez P; González T; Arnan M; Pomares-Marín H; Carreño-Tarragona G; Chen-Liang TH; Herranz MT; García-Palenciano C; Morales ML; Jerez A; Lozano ML; Teruel-Montoya R; Pelegrín P; Ferrer-Marín F
Cell Rep Med; 2023 Dec; 4(12):101329. PubMed ID: 38118408
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax.
Bataller A; Bazinet A; DiNardo CD; Maiti A; Borthakur G; Daver NG; Short NJ; Jabbour EJ; Issa GC; Pemmaraju N; Yilmaz M; Montalban-Bravo G; Takahashi K; Loghavi S; Garcia-Manero G; Ravandi F; Kantarjian HM; Kadia TM
Blood Adv; 2024 Feb; 8(4):927-935. PubMed ID: 38113472
[TBL] [Abstract] [Full Text] [Related]
17. JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers.
Lu X; Yu R; Li Z; Yang M; Dai J; Liu M
Cancer Lett; 2024 Feb; 582():216517. PubMed ID: 38101609
[TBL] [Abstract] [Full Text] [Related]
18. [Clinical Analysis of Infants with Acute Lymphoblastic leukemia (18 cases)].
Li KL; Xiong H; Li H; Wang Z; Chen Z; Yang L; Lu WJ; Qi SS; Sun M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1670-1675. PubMed ID: 38071044
[TBL] [Abstract] [Full Text] [Related]
19. Atypical CML: diagnosis and treatment.
Breccia M
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):476-482. PubMed ID: 38066919
[TBL] [Abstract] [Full Text] [Related]
20. Distinct karyotypic and mutational landscape in trisomy AML.
Lam SSY; Tsui SP; Fung CY; Saw NY; Javed A; Ip AHW; Ma ESK; Leung AYH
Br J Haematol; 2024 Mar; 204(3):939-944. PubMed ID: 38054248
[TBL] [Abstract] [Full Text] [Related]
[Next]
